BRAIN and NERVE Shinkei Kenkyu no Shinpo Volume 68, Issue 12 (December 2016)

Novel Therapy in Guillain-Barré Syndrome Motoi Kuwahara 1 , Susumu Kusunoki 1 1Department of Neurology, Kindai University Faculty of Medicine Keyword: ギラン・バレー症候群 , 新規治療法 , エクリズマブ , J-GOS , Guillain-Barré syndrome , novel therapy , Eculizumab , Japan GBS outcome study (J-GOS) pp.1423-1429
Published Date 2016/12/1
  • Abstract
  • Look Inside
  • Reference


The efficacy of plasma exchange (PE) and intravenous immunoglobulin (IVIg) therapies for Guillain-Barré syndrome have been established by numerous randomized controlled trials. However, 10-20 % of GBS patients cannot walk without aid after one year from onset of the disease. Thus, new treatment is required for these intractable cases. The Japan GBS outcome study (J-GOS) has been conducted to identify clinical or biological markers that predict the prognosis of Japanese GBS patients at an early stage. In the future, we expect to provide intractable patients so predicted with novel therapy, including molecular target drugs.

Copyright © 2016, Igaku-Shoin Ltd. All rights reserved.


BRAIN and NERVE-神経研究の進歩
68巻12号 (2016年12月)
電子版ISSN 1344-8129 印刷版ISSN 1881-6096 医学書院